Digital Therapeutics Alliance Boosts European Presence

The Digital Therapeutics Alliance (DTA) has expanded its European membership by announcing that S3 Connected Health is joining the industry body.

DTA is a global non-profit trade association which aims to broaden the understanding, adoption, and integration of clinically-validated digital therapeutics in healthcare through education, advocacy, and research.

Launched in October 2017, DTA is committed to engaging with patients, providers, payers and regulators to define and develop meaningful resources to guide and scale adoption of digital therapeutics (DTx). It works with industry leaders to aid the introduction of tested and trustworthy digital solutions in healthcare. The Alliance has now grown its global membership to 20 companies, bringing together wide-ranging expertise from firms engaged in implementing digital therapeutics in drug discovery and clinical pathways.

In the US, DTA supports the work of the US Food and Drug Administration (FDA) and related efforts to drive regulatory, clinical, organizational and financial integration of digital therapeutics into mainstream healthcare. The expansion of its European presence will enable the Alliance to progress parallel efforts across the diverse and varied European healthcare ecosystem.

S3 Connected Health specializes in the design and development of digital therapeutics and digital health solutions. Focused on addressing the problem of therapy management and medication non-adherence, which is estimated to account for hundreds of thousands of premature deaths globally each year, costing the pharmaceutical industry around $637bn in lost revenues and compromising positive patient health outcomes.

Having pioneered successful, clinically-validated telehealth solutions in the UK and Italy over the past decade, S3 Connected Health has invested heavily in its Affinial platform, a solution-as-a-service that uses behavioral science techniques and user data to deliver individualized support to help patients to manage their therapy and remain adherent to medications across multiple conditions.

S3 Connected Health will bolster DTA’s presence in Europe and provide a platform for increased understanding of the regulatory, legal and reimbursement pathways on behalf of digital therapeutics firms within institutions including the European Medicines Agency.